Business Context and Reporting Period
This Form 8-K Current Report was filed by ImmuCell Corporation on March 12, 2026. The report addresses corporate governance changes regarding the Board of Directors effective April 1, 2026.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
- Director Departure: Steven A. Rosgen tendered his resignation from the Board of Directors, effective April 1, 2026, following a prior notice that he would not seek re-election.
- Director Election: The Board elected Kathy V. Turner to fill the vacancy created by Mr. Rosgen's retirement, effective April 1, 2026.
- Committee Appointments: Ms. Turner was appointed to the Audit Committee and named Chair of the Compensation and Stock Option Committee, effective April 1, 2026.
Management Commentary and Risks
New Director Background: Ms. Turner brings over three decades of commercial executive leadership experience in global healthcare and animal health. Her recent roles include Chief Marketing Officer and Senior Vice President of International Operations at IDEXX Laboratories (2014–2023) and Board service at Elanco Animal Health (April 2024–May 2025). She previously spent nearly 30 years at Abbott Laboratories.
Compensation Disclosure: The Company stated it is not aware of any transaction involving Ms. Turner requiring disclosure under Item 404(a) of Regulation S-K.
Risks and Contingencies: No specific financial risks or contingencies were disclosed in this filing.
Key Facts for Investor Verification
- Verify the effective date of the Board composition change (April 1, 2026).
- Review the press release (Exhibit 99.1) for additional details on Ms. Turner's qualifications and the Board's rationale.
- Confirm that no undisclosed compensatory arrangements exist for the new director as stated in the filing.
- Note that this filing contains no financial results; refer to the most recent 10-K or 10-Q for financial metrics.